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SUMMIT supports the efficiency and cardiovascular safety of LABA and ICS in COPD patients
at cardiovascular risk http://ow.ly/p6Is300ffoc
Background
Chronic obstructive pulmonary disease (COPD) is a major cause of death and disability worldwide.
Although COPD primarily affects the lungs, it has become clear that systemic effects of COPD significantly
contribute to its severity and overall mortality. Due to its high prevalence in the older population, and
smoking as a shared risk factor, cardiovascular disease (CVD) is of particular importance [1]. Indeed, more
patients with COPD die from CVD than from COPD itself [2–5]. Research indicates a number of
mechanisms that explain this relationship, including systemic inflammation, physical inactivity,
neurohumoural activation, arrhythmias, endothelial dysfunction and a greater fall in pleural pressure during
inspiration [6]. Thus, bronchodilation might positively impact on CVD. In line with that reasoning,
endothelial function and blood pressure were improved after lung volume reduction surgery in patients
with severe COPD [7]. Furthermore, retrospective data from the National Emphysema Treatment Trial
suggest that long-acting β2-agonists (LABA) reduce mortality [8]. There are also data suggesting that
inhaled corticosteroids (ICS) may have a beneficial effect on the risk of cardiovascular events in COPD,
possibly by decreasing systemic inflammation [9].
Besides the well-characterised positive effects of inhaled therapy, safety issues remain. Both LABA and
long-acting muscarinic antagonists (LAMA), as well as fixed combinations of both, and the combination
of ICS and LABA, seem to be safe when used in the appropriate dose in patients with stable CVD [10, 11].
However, the cardiac safety of LABA and LAMA is less evident when used in COPD patients with
uncontrolled, substantial or acute CVD [10]. Therefore, the Study to Understand Mortality and Morbidity
in COPD (SUMMIT), focusing on COPD patients with increased cardiovascular risk, was well positioned
to inform us of the cardiovascular safety and effects of ICS and LABA.
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SUMMIT is a placebo-controlled, double-blind, randomised, parallel-group, multicentre trial [6]. COPD
patients with moderate airflow limitation (⩾50% and ⩽70% predicted forced expiratory volume in 1 s (FEV1))
and a history of CVD or increased risk of CVD were randomised 1:1:1:1 to one of four double-blind
treatment groups: placebo, fluticasone furoate (FF), vilanterol (VI), or a combination of FF and VI [6]. This
was an endpoint-driven study designed to have 90% power to detect a 30% reduction in all-cause mortality
with FF/VI compared to placebo [6]. Clinical events were adjudicated meticulously by an endpoint
committee. With >16000 patients included, the primary endpoint, all-cause mortality, showed a 12% relative
reduction with FF/VI compared to placebo, which was not statistically significant (p=0.137) [12].
The predefined secondary endpoints were 1) the effect of FF/VI compared with placebo on the rate of decline
in FEV1, and 2) the effect of FF/VI compared with placebo on a cardiovascular composite endpoint
comprised of on-treatment cardiovascular death, myocardial infarction, stroke, unstable angina and transient
ischaemic attack [6].
Combination therapy reduced the secondary endpoint, rate of FEV1 decline, by 8 mL per year compared
with placebo (p=0.019) [12]. When analysing the monotherapy arms, this effect was related to the inhaled
corticosteroid use rather than the β2-agonist use (table 1). For the other secondary endpoint, the risk of
cardiovascular events was not significantly different between FF/VI and placebo (p=0.478) [12]. It must be
kept in mind, however, that these were secondary endpoints and the primary endpoint was negative, thus
making inferences problematic.
Other prespecified endpoints demonstrated an improvement compared to placebo in the rate of moderate
and severe exacerbations (table 1). There was no difference between the treatment groups in pneumonia
and other adverse events. Analysis of subgroups such as patients with atrial fibrillation or a myocardial
infarction are ongoing and are likely to be available in subsequent publications.
Comments
The SUMMIT trial is the largest COPD randomised, placebo-controlled trial ever. The study investigators
report a negative finding, albeit that the direction of effect was as anticipated. SUMMIT was designed to
have 90% power to detect a 30% reduction in the risk of all-cause mortality on FF/VI compared with
placebo [6]. This assumption might have been too optimistic. ClinicalTrials.gov and other resources [6] do
not inform us about previous studies that led to this assumption. Two preceding large studies [4, 13] with
mortality signals included patients with more severe COPD and less cardiovascular risk, making inferences
for SUMMIT challenging.
Physicians are often hesitant to treat airway obstruction with inhaled LABA in patients with CVD [14].
The currently presented data of the large and meticulously controlled SUMMIT trial in a moderately
dyspnoeic COPD population at increased cardiovascular risk do not indicate major signals for cardiac
safety. These important and timely data should reassure physicians on the use of LABA in moderate
COPD patients at cardiovascular risk in general. However, questions on subgroups such as patients with
atrial fibrillation or recent myocardial infarction remain, and this clinical relevant information is be
eagerly awaited.
By their systemic effects, concurrent use of LABA and LAMA, i.e. dual bronchodilation, might potentially
increase cardiovascular effects [10]. Recent phase III studies of dual bronchodilators (some of them using
Holter data) did not exhibit conclusive safety signals [10, 15, 16]. However, these trials were smaller than
SUMMIT and have not investigated a cohort with increased cardiovascular risk. SUMMIT did not permit
tiotropium at baseline but following severe exacerbation, tiotropium could be added. Therefore, SUMMIT
TABLE 1 Main results of the SUMMIT trial
Placebo FF VI FF/VI p-value#
Mortality 275 (6.7%) 251 (6.1%) 265 (6.4%) 246 (6.0%) 0.137
FEV1 decline mL·year−1 mean±SE 46±2.5 38±2.4 47±2.4 38±2.4 0.019
Cardiovascular endpoint¶ 173 (4.2%) 161 (3.9%) 180 (4.4%) 174 (4.2%) 0.478
Moderate and severe exacerbations per year 0.35 0.31 0.31 0.25 <0.0001
Severe exacerbations per year 0.07 0.06 0.06 0.05 0.0004
Pneumonia cases per 100 person-years 3.8 4.2 2.8 3.9 >0.05
SUMMIT: Study to Understand Mortality and Morbidity in COPD; FF: fluticasone furoate; VI: vilanterol; FEV1: forced expiratory volume in 1 s.
#: FF/VI compared to placebo; ¶: on-treatment cardiovascular death, myocardial infarction, stroke, unstable angina and transient ischaemic attack.
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TABLE 2 Comparison between the three largest randomised placebo-controlled trials in chronic obstructive pulmonary disease (COPD) history: SUMMIT, TORCH and
UPLIFT
SUMMIT TORCH UPLIFT
First author [ref.], year VESTBO [12], 2016 CALVERLEY [4], 2007 TASHKIN [23], 2008
Duration years Median 1.8 3 4
Subjects 16485 ITT (16568 total) 6112 (6184 in post hoc analysis) 5993 (5994 in post hoc analysis)
Inclusion criteria COPD II
Age 40–80 years
⩾10 pack-years
FEV1/FVC <70%, and post-BD FEV1 ⩾50
and ⩽70% pred
mMRC ⩾2





FEV1/FVC ⩽70% and pre-BD FEV1 <60%
pred with poor reversibility
Able to use inhaler and relief medication correctly




FEV1/FVC ⩽70% at visits 1 and 2, and
post-BD FEV1 ⩽70% pred
Able to use inhaler and perform
acceptable PFTs
Maintained on stable respiratory
medications








Exacerbation during run-in period
Asthma or current other respiratory disorders






Recent other investigational drugs
Drug (component) hypersensitivity
Exacerbation during run-in period






Recent other investigational drugs
Oral corticosteroid use at unstable
doses or ⩾10 mg·day−1
Exacerbation before or
during run-in period
Women able to conceive, pregnant or
nursing
Specific disease exclusion criteria Current severe heart failure (NYHA
class IV, ejection fraction <30%)
ICD
End-stage chronic renal disease
Conditions other than vascular disease
or COPD likely to cause death within
3 years or study incompletion
Serious, uncontrolled disease or psychological
disorders likely to interfere results or to
cause death within 3 years
Alcohol, drug or solvent abuse
Significant diseases likely to interfere
results or participants’ participation
History of myocardial infarction (within
last 6 months)
Cardiac arrhythmia or heart failure




Symptomatic BPH or PBNO






























Comparator Placebo (all prior use of ICS and
LABA/LAMA discontinued)
Placebo (SABA/SAMA, theophyllines, smoking cessation
therapy, intermittent oxygen therapy and short courses
of oral corticosteroids permitted)
Placebo (use of all respiratory
medications except inhaled
anticholinergic drugs permitted)
Drug of investigation Vilanterol 25 µg plus fluticasone
furoate 100 µg
Salmeterol xinafoate 50 µg plus
fluticasone propionate 500 µg
Tiotropium 18 µg
Third arm Vilanterol 25 µg Salmeterol xinafoate 50 µg
Fourth arm Fluticasone furoate100 µg Fluticasone propionate 500 µg
Device Novel dry-powder inhaler All Diskus/Accuhaler HandiHaler, twice daily
Primary endpoint All-cause mortality (negative) All-cause mortality (negative) Rate of decline in trough and 90-min
post-BD FEV1 (negative)
Cardiac/mortality endpoint All-cause mortality (p=0.137) and
composite cardiovascular endpoint
(p=0.478) were not significantly
decreased for combination therapy
compared to placebo
All-cause mortality was numerically lower for
combination therapy or salmeterol compared to placebo
Mortality in fluticasone group was numerically higher
Post hoc analysis: salmeterol alone or in combination
did not increase the risk of cardiovascular events
Cardiac AEs lower in tiotropium
treated except for angina and cardiac
failure
Mortality lower in tiotropium group
(14.4%) versus placebo (16.3%)
Post hoc analysis: decreased cardiac
mortality in tiotropium treated
SUMMIT: Study to Understand Mortality and Morbidity in COPD; TORCH: Towards a Revolution in COPD Health; UPLIFT: Understanding Potential Long-term Impacts on Function with
Tiotropium; ITT: intention to treat; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; BD: bronchodilator; mMRC: modified Medical Research Council dyspnoea score; PFT:
pulmonary function test; LVRS: lung volume reduction surgery; LTOT: long-term oxygen therapy; LTOC: long-term oral corticosteroid therapy; NYHA: New York Heart Association; ICD:
implantable cardioverter defibrillator; NAG: narrow-angle glaucoma; BPH: benign prostatic hyperplasia; PBNO: primary bladder-neck obstruction; ICS: inhaled corticosteroids; LABA:
long-acting β2-agonists; LAMA: long-acting muscarinic antagonists; SABA: short-acting β2-agonists; SAMA: short-acting muscarinic antagonists; AE: adverse event.
#: established
coronary artery disease, established peripheral vascular disease, previous stroke, previous myocardial infarction or diabetes mellitus with target organ disease, or if ⩾60 years of age



























provides only limited data on dual bronchodilation and thus is unable to comment on safety issues of
LABA plus LAMA.
The improvement in FEV1 and the reduction of moderate and severe exacerbations with FF, VI and FF/VI
confirms effects that were seen in previous studies, such as TORCH (Towards a Revolution in COPD
Health) and a meta-analysis [4, 16]. Besides, the effect of FF/VI on FEV1 was smaller than in trials
evaluating dual bronchodilation [10, 15, 16]. Effects on quality of life were not reported.
SUMMIT is the largest study showing a reduction in the rate of FEV1 decline in a predefined analysis. As
discussed above, secondary endpoints in a study with a negative primary endpoint have to be interpreted
with caution. Nevertheless, clinically, it is reasonable to assume that the two endpoints are independent of
each other since a small effect on the rate of FEV1 decline (8mL per year) will not impact mortality.
However, it is questionable whether this small difference observed over a relatively short time period
(median study exposure 1.8 years) has clinical relevance, especially since recent trials show clinically
relevant effects of dual bronchodilation compared to salmeterol plus fluticasone [17]. Further studies
might define subgroups where ICS affect disease progression, such as in COPD patients with blood
eosinophilia or a Th2 gene expression profile [18–20]. Unfortunately, blood eosinophils were not routinely
evaluated in SUMMIT.
Compared to placebo, the combination treatment had no significant effect on the incidence of pneumonia
in SUMMIT [12]. This is in contrast with previous studies and a meta-analysis [21, 22]. This contrast
might be explained by the different patient characteristics or different inclusion and exclusion criteria
(table 2). Lung function was less compromised (higher FEV1) and CVD more common in SUMMIT
participants than in previous large COPD cohorts (table 2) [24, 25]. The relatively low dose of the ICS
may also have been beneficial because the pneumonia risk is dose dependent [24]. In line with ICS
meta-analyses, the phase III COPD studies using FF/VI showed increased pneumonia rates with increasing
FF dose [21, 24]. Finally, the relatively short mean follow-up might also have contributed to the observed
pneumonia rates in SUMMIT [12, 24].
Was the therapy used in SUMMIT the optimal inhaled treatment? A recent trial available only as press
release shows a reduction in exacerbations with the dual bronchodilator indacaterol/glycopyrronium as
compared to the LABA/ICS salmeterol/fluticasone [17]. The press release does not clarify whether this
finding is driven by the reduction of severe, moderate or mild (mainly lung function driven) exacerbations,
but it would be interesting to know what the effects of dual bronchodilation in a SUMMIT-like population
are. However, given that inhaled therapy in COPD improves convincing clinical endpoints such as lung
function, exacerbations, exercise capacity and quality of life, another large placebo-controlled
bronchodilator study with mortality as the primary endpoint is unlikely to be performed for ethical and
financial reasons [4, 23]. In this regard, it appears that we have reached the summit.
Similar to previous COPD trials, 47% of the SUMMIT patients were active smokers [12]. Smoking
cessation is the most effective way to reduce pulmonary as well as cardiovascular morbidity and mortality,
and thus remains of principal importance in COPD treatment [26].
Conclusion
SUMMIT clearly supports the efficiency and cardiovascular safety of LABA and ICS in COPD patients at
cardiovascular risk. Subsequent subgroup analysis is likely to provide further important information.
Nevertheless, diagnosing and targeting underlying CVD might be a more effective way to address
mortality in COPD. Accordingly, β-blockade and angiotensin receptor blockade targeting neurohumoural
activation, as is present in COPD, shows promise [3, 27].
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